HHS is proposing major changes to HIPAA for the first time in more than a decade, aiming to strengthen cybersecurity protocols for electronic health data. Healthcare cybersecurity leaders are mainly in favor of the proposal — though there are some concerns that smaller providers will struggle with the financial and operational burdens of compliance.
Gilead Sciences is acquiring LEO Pharma's oral small molecule inhibitors of STAT6, a protein key to two validated inflammation pathways. Other STAT6 drug developers include Kymera Therapeutics and Sanofi-partnered Recludix Pharma, which is presenting this week during the J.P. Morgan Healthcare Conference.
Implementing a thorough federal privacy law and broadening HIPAA protections to include new mHealth technologies are crucial steps in enhancing personal data security. Equally important, companies and developers should adhere to strict ethical standards and robust security protocols during app development to protect users' sensitive information.
AI holds a lot of promise in supporting employer-sponsored healthcare, including improving patient navigation and billing, according to a new report from Morgan Health.
The choices we make now will determine not just the future of healthcare, but the kind of society we leave to our children. Will we continue to allow faceless algorithms to decide who lives and who suffers? Or will we finally reclaim healthcare's moral center and build a system worthy of our highest values?
In this episode, we're joined by Kathryn Schubert, president and CEO of the Society for Women's Health Research. Schubert discusses the trends in women's health that defined 2024 and what we can expect in the coming year.
No comments